UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Holdings in The Clorox Company (NYSE:CLX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of The Clorox Company (NYSE:CLX - Free Report) by 12.4% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,115,772 shares of the company's stock after acquiring an additional 123,200 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.90% of Clorox worth $181,213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Redwood Park Advisors LLC bought a new stake in Clorox during the 4th quarter valued at $26,000. Millstone Evans Group LLC bought a new stake in Clorox during the 4th quarter valued at $31,000. Asset Planning Inc bought a new stake in Clorox during the 4th quarter valued at $32,000. GKV Capital Management Co. Inc. bought a new stake in Clorox during the 4th quarter valued at $32,000. Finally, Aster Capital Management DIFC Ltd bought a new stake in Clorox during the 4th quarter valued at $33,000. Institutional investors own 78.53% of the company's stock.

Insiders Place Their Bets

In other news, Director Pierre R. Breber purchased 4,000 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the acquisition, the director now directly owns 4,000 shares in the company, valued at $546,280. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.57% of the company's stock.

Clorox Trading Up 0.3%

CLX stock traded up $0.37 during trading on Wednesday, reaching $130.73. The company had a trading volume of 400,881 shares, compared to its average volume of 1,333,721. The Clorox Company has a 52 week low of $127.60 and a 52 week high of $171.37. The company has a market cap of $16.11 billion, a P/E ratio of 35.72, a PEG ratio of 2.62 and a beta of 0.60. The business has a 50 day moving average of $139.05 and a 200 day moving average of $151.85. The company has a debt-to-equity ratio of 20.52, a current ratio of 0.94 and a quick ratio of 0.60.

Clorox (NYSE:CLX - Get Free Report) last released its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). Clorox had a return on equity of 316.87% and a net margin of 6.38%. The company had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.74 billion. During the same period in the previous year, the company earned $1.71 earnings per share. Clorox's quarterly revenue was down 8.0% on a year-over-year basis. As a group, sell-side analysts forecast that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently commented on the stock. DA Davidson reduced their price target on shares of Clorox from $171.00 to $169.00 and set a "neutral" rating for the company in a research report on Wednesday, February 5th. Barclays reduced their price target on shares of Clorox from $134.00 to $129.00 and set an "underweight" rating for the company in a research report on Wednesday, May 7th. Morgan Stanley reduced their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. UBS Group reduced their price target on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Finally, Wells Fargo & Company reduced their price target on shares of Clorox from $145.00 to $142.00 and set an "equal weight" rating for the company in a research report on Tuesday, May 6th. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Clorox presently has a consensus rating of "Hold" and a consensus target price of $151.23.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.